Metronomic chemotherapy (mCHT), defined as continuous administration of low-dose
chemotherapeutic agents with no or short regular treatment-free intervals, was first …

Background: As disease control and quality of life play a leading role in metastatic breast
cancer (MBC), metronomic chemotherapy (MCT) is gaining popularity alongside …

Background Despite the high incidence of metastatic breast cancer and its related mortality
in the elderly population, our knowledge about optimal treatment for older patients with …

To improve the therapeutic efficacy of breast cancer (BC), an intelligent tri-responsive
vehicle based on core–shell structured gold nanorods (GNR)@ mesoporous SiO2 (MS) …

Methotrexate (MTX), a frequently used chemotherapeutic agent, has limited water solubility,
leading to rapid clearance even in local injections. In the present study, we developed folic …

In this study, a bovine serum albumin-decorated zeolitic imidazolate framework (ZIF-8@
BSA) was used to enhance the anticancer and antimetastatic properties of methotrexate …

Purpose There is growing interest in low-dose metronomic chemotherapy (LDMC) in
metastatic breast cancer (MBC). In this retrospective case–control analysis, we compared …

Breast cancer (BRCA) is the most fatal malignancy of women. Immunotherapy has greatly
improved the prognosis of advanced BRCA. Cellular senescence contributes to …

Introduction Breast cancer (BC) remains a prevalent and challenging malignancy among
women, with significant advancements in treatment strategies over the past decades …

Purpose Metronomic chemotherapy has the potential to offer tumor control with reduced
toxicity when compared to standard dose chemotherapy in patients with metastatic breast …